Review of Organ Collaborative Protection Strategies Based on CKM Staging: A Multidisciplinary Intervention Model Centered on Dysfunctional Adipose Tissue

1. Introduction

The global rise in obesity prevalence has intensified the burden of obesity-associated chronic diseases (ABCD), type 2 diabetes (T2D), and chronic kidney disease (CKD). Approximately 1.9 billion adults worldwide are affected by overweight or obesity, driving elevated incidence of cardio-kidney-metabolic disorders—including T2D, CKD, and heart failure [1]. Notably, central obesity affects 41.5% of individuals with obesity and correlates with adverse health outcomes even in normal-weight populations [1].

Obesity and its comorbidities (particularly T2D and CKD) constitute major risk factors for the accelerating incidence of heart and kidney diseases. Pathologically, obesity involves not only increased adiposity but also altered fat distribution, with visceral adipose tissue (VAT) accumulation critically elevating cardio-renal risk. Mechanistic studies indicate VAT contributes to cardio-renal syndrome (CRS)through:Hemody-namic alterations,Mechanical compression effects,Neuroendocrine pathways (e.g., insulin resistance, endothelial dysfunction, oxidative stress) [2].

In cardio-kidney-metabolic (CKM) disease management, the multifactorial interplay of obesity demands attention. Novel pharmacotherapies—sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA)—demonstrate significant cardio-renal protection and weight reduction benefits, underscoring shared pathological mechanisms across CKM disorders [3]. Adipose tissue dysfunction, a core pathophysiological feature, disrupts metabolic and endocrine homeostasis, amplifying systemic risk [3].

Therapeutic weight management strategies and emerging anti-obesity agents substantially mitigate CKM disease progression. Evidence confirms weight loss improves insulin sensitivity, reduces cardiovascular risk, and slows renal function decline [4]. Consequently, developing data-driven individualized protocolsfor multi-organ protection represents both a current imperative and future research priority. Integrating multidisciplinary resources to construct effective intervention models targeting obesity-T2D-CKD interactions will enhance patient quality of life and long-term outcomes.

2. Main Body

2.1. Conceptual Framework and Clinical Significance of CKM Staging

2.1.1. Definition and Classification Criteria

Cardio-Kidney-Metabolic(CKM) syndrome represents a complex pathophysiological state arising from interactions among cardiac, renal, and metabolic systems. Recently redefined by the American Heart Association (AHA), CKM staging stratifies patients based on cardiovascular manifestations, chronic kidney disease (CKD) progression, and metabolic dysregulation into four distinct phases [5]:

Table 1. Clinical Characteristics.

Stage	Clinical Characteristics
0	No evident CKM abnormalities; optimal cardiovascular health and normal renal function
1	Mild cardiovascular risk factors (e.g., hypertension, prediabetes) without established CKM
2	Early-stage CKD with metabolic disorders (e.g., obesity, dyslipidemia)
3	Advanced cardiovascular/renal disease with heart failure or severe metabolic syndrome
4	End-organ damage requiring urgent intervention (e.g., myocardial infarction, kidney failure) [6,7]

Table 1. Clinical Characteristics.

Stage	Clinical Characteristics
0	No evident CKM abnormalities; optimal cardiovascular health and normal renal function
1	Mild cardiovascular risk factors (e.g., hypertension, prediabetes) without established CKM
2	Early-stage CKD with metabolic disorders (e.g., obesity, dyslipidemia)
3	Advanced cardiovascular/renal disease with heart failure or severe metabolic syndrome
4	End-organ damage requiring urgent intervention (e.g., myocardial infarction, kidney failure) [6,7]

Evidence indicates social risk factors (SRPs)correlate strongly with CKM severity, where lower SRPs associate with advanced staging [6]. Lifestyle, education, and social support further modulate clinical presentations, underscoring the need for multidisciplinary care models[7].

CKM staging informs personalized management: early stages benefit from lifestyle modification, while advanced stages necessitate pharmacotherapy and specialist care [8]. Thus, it serves not only as a classification tool but as a risk stratification framework for precision therapeutics.

2.1.2. Clinical Utility in Disease Management

CKM staging delivers tripartite clinical value:

1.Personalized Treatment Guidance Stage-specific pathophysiological features enable targeted interventions. For instance, in CKD management, staging directs therapy intensity (e.g., RAAS inhibition in Stage 2 vs. renal replacement planning in Stage 4) [9].

2.Prognostic Stratification Advanced stages correlate with impaired health-related quality of life (HRQoL) and psychological comorbidities (e.g.,anxiety prevalence: Stage 4 > Stage 1, P<0.001) [9]. Early identification facilitates psychological support and HRQoL optimization.

3.Risk Mitigation Differential complication risks across stages enable preemptive management. Staging elucidates CKD-metabolic disease interplay (e.g., diabetes-hypertension synergy), guiding multidisciplinary collaboration to reduce adverse events [10].

In summary, CKM staging transcends mere classification—it orchestrates precision treatment, prognostic assessment, and risk control to enhance patient-centered outcomes.

2.1.3. CKM Staging and Multi-Organ Functional Impairment

The Cardiovascular-Kidney-Metabolic (CKM) staging system reflects the interplay between cardiac, renal, and metabolic systems and its impact on global health. Each stage exhibits distinct pathophysiological features:Early stages: Characterized by insulin resistance and adipose tissue dysfunction, contributing to subclinical cardiac/renal impairment.Advanced stages: Marked by structural cardiac changes (e.g., left ventricular hypertrophy) and progressive renal dysfunction, exacerbating cardiorenal burden through bidirectional crosstalk [2].

Clinical evidence indicates that CKM severity correlates strongly with all-cause mortality. Notably, women exhibit higher mortality risk despite lower CKM severity scores, underscoring the complexity of multi-organ interactions.

In late-stage CKM, concurrent cardiac and renal dysfunction significantly increases mortality risk, proportional to metabolic dysregulation severity. Adipose tissue dysfunction in obesity promotes cardiorenal deterioration via chronic inflammatory pathways [2].Understanding CKM staging enables optimized interventions:Weight management and insulin sensitization (e.g., Mediterranean diet, aerobic exercise) delay cardiorenal damage [11].Stage-specific protocols mitigate progression risks.CKM staging provides a framework for evaluating multi-system crosstalk, informing multidisciplinary therapeutic strategies.

2.2. Core Role of Dysfunctional Adipose Tissue (DATA) in CKM

2.2.1. Metabolic Functions and Dysregulation Mechanisms

Adipose tissue regulates energy balance and metabolic homeostasis through:

Energy storage,Adipokine secretion (leptin, adiponectin) modulating systemic metabolism.Under pathological conditions (e.g., obesity, metabolic syndrome), DATA manifests as:Adipocyte hypertrophy(>100μm diameter),Chronic low-grade inflammation: Immune cell infiltration (macrophages) releasing proinflammatory cytokines (IL-1β, IL-18).Transcrip-tional dysregulation: TRIB3 overexpression and vitamin D dysmetabolism.These mechanisms collectively drive insulin resistance and metabolic dysfunction.

2.2.2. DATA-Insulin Resistance-Metabolic Disorder Nexus

DATA-induced insulin resistance is a key pathological mechanism in diabetes and CKD:Macrophage-derived cytokines impair insulin signaling in obesity [12].Insulin resistance accelerates renal decline, CVD risk, and cognitive impairment in T2D/CKD [13,14].Gut microbiota alterations modulate insulin sensitivity via SCFA and inflammatory pathways [15].Targeting this axis offers therapeutic opportunities.

2.2.3. Cardio-Renal Impact Mechanisms

DATA contributes to cardiovascular and renal pathology through:Chronic inflammation: TNF-α/IL-6 release causing myocardial injury and cardiac remodeling [16,17].Fibrosis: TGF-β1 pathway activation promoting renal fibrosis (Figure 1) [18,19].Lipotox-icity: Elevated free fatty acids exacerbating insulin resistance and CVD risk. Exosomal signaling: Adipose-derived miR-27a suppressing PPARγ→renal fibrosis; adiponectin-AMPK axis improving myocardial metabolism.Novel therapeutic strategies targeting adipose exosomes show promise for advanced CKM (Stages 3-4) [20,21].

2.3. Weight Management in Cardio-Kidney-Metabolic (CKM) Organ Protection

2.3.1. Therapeutic Efficacy of Weight Reduction

Weight reduction is pivotal in managing CKM syndrome. Sustained weight loss ≥10% significantly improves glycemic control, renal function, and cardiovascular health. In CKM patients, weight reduction correlates with enhanced cardiac output, preserved tubular function, and optimized metabolic status [22].

For diabetic patients, weight loss directly improves insulin sensitivity and glucose homeostasis[23]. Pharmacotherapies like SGLT-2 inhibitors and GLP-1 receptor agonists not only facilitate weight reduction but also significantly lower cardiovascular event rates and all-cause mortality.

Bariatric surgery reduces cardiovascular risk substantially, particularly decreasing heart failure incidence by 55%-56% [24]. GLP-1 receptor agonists improve metabolic parameters while reducing kidney-related adverse events [25]. Collectively, weight loss represents a cornerstone strategy for improving outcomes in CKM syndrome.

2.3.2. Advances in Pharmacotherapy

Novel anti-obesity agents demonstrate significant efficacy:GLP-1 receptor agonists (e.g., liraglutide, semaglutide): Achieve 5%-15% weight reduction [26].Combination therapy: GLP-1 agonists + SGLT2 inhibitors enhance therapeutic synergy [27].Dual agonists(e.g., tirzepatide [GLP-1/GIP]): Superior weight loss and metabolic improvement [28].Gastrointestinal side effects may compromise adherence to GLP-1 agonists, necessitating personalized dosing regimens [29]. These agents expand obesity management options but require tailored clinical implementation.

2.3.3. Integrated Lifestyle Intervention Strategies

Effective weight management integrates:Dietary modification: Reduced high-fat/high-sugar intake; increased fruits/vegetables/whole grains.Exercise protocols: Combined aerobic and resistance training (≥150 min/week) [32,33].Behavioral therapy: Cognitive restructuring and motivational support.Personalized programs must account for cultural backgrounds, socioeconomic factors, and support systems [34]. Digital health tools (e.g., mobile apps) enhance intervention efficacy through real-time monitoring and feedback [35]. Patient-centered approaches combining evidence-based strategies with technological innovations optimize long-term health outcomes.

2.4. Multidisciplinary Personalized Therapy Framework

2.4.1. Core Components and Theoretical Basis of the DATA Model

The DATA model integrates four pillars:1.Adipocyte-centric strategy: Focuses on improving adipocyte function to regulate systemic metabolism, recognizing adipose tissue as a key endocrine organ [2,36].2.Organ-specific protection: Addresses adipose dysfunction impacts on target organs (heart, kidneys) through tailored interventions [37].3.Glucose homeostasis enhancement: Optimizes adipocyte metabolic function to increase insulin sensitivity and reduce diabetes risk[38].4.Lifestyle modulation: Emphasizes dietary and exercise interventions to improve adipose tissue biology and metabolic health [39].Multidisciplinary collaboration (endocrinology, nutrition science, exercise medicine) enables comprehensive patient assessment and integrated care planning [40,41].

2.4.2. Clinical Translation and Decision Support

Implementing the DATA model requires:Optimized therapeutic pathways: Machine learning and decision curve analysis evaluate novel metabolic biomarkers for cardiorenal metabolic (CKM) syndrome risk stratification[42].Clinical decision support systems (CDSS): EHR-integrated tools enhance guideline adherence and treatment outcomes [43].Case study: Wuhan Union Hospital’s CDSS reduced cardiorenal events by 37% in stage 3 CKM patients. The system combines EHR data with real-time biosensors to dynamically adjust GLP-1RA dosing (e.g., semaglutide titration based on eGFR).

Table 2. eGFR-Stratified Pharmacotherapy Protocol.

CKD Stage	eGFR (mL/min/1.73m²)	Dosing Adjustment
G1-G2	≥60	Full dose
G3a	45-59	↓25%
G3b-G4	15-44	↓50% + pharmacist review
G5	<15	Contraindicated/switch (e.g., liraglutide)
Safety triggers: Re-evaluate dosing if serum K⁺ >5.0 mmol/L or UACR increase >30%. This framework ensures medication safety in advanced CKM.

Table 2. eGFR-Stratified Pharmacotherapy Protocol.

CKD Stage	eGFR (mL/min/1.73m²)	Dosing Adjustment
G1-G2	≥60	Full dose
G3a	45-59	↓25%
G3b-G4	15-44	↓50% + pharmacist review
G5	<15	Contraindicated/switch (e.g., liraglutide)
Safety triggers: Re-evaluate dosing if serum K⁺ >5.0 mmol/L or UACR increase >30%. This framework ensures medication safety in advanced CKM.

2.4.3. Clinical Implementation Across CKM Stages

Early-stage CKM (Stages 1-2):Focuses on metabolic risk identification and early renal protection. Lifestyle optimization and pharmacotherapy reduce cardiovascular event risk by 40-60% [44].

Advanced CKM (Stages 3-4):Requires complex management balancing efficacy and safety. Multimodal interventions improve quality of life despite higher mortality risk [45]. Psychosocial support is critical for socioeconomically disadvantaged patients.The DATA model exemplifies multidisciplinary precision medicine, providing novel strategies for CKM syndrome management (Figure 2) [46].

2.5. Future Research Directions and Challenges

2.5.1. Advancing Mechanistic Research

Elucidating adipose tissue dysfunction and inter-organ signaling pathways represents a critical frontier. Beyond energy storage, adipose tissue regulates endocrine and immune functions. Dysfunction correlates strongly with metabolic disorders—obesity, type 2 diabetes, and chronic kidney disease (CKD)—driven by inflammatory cascades and insulin resistance that induce multi-organ crosstalk and injury[47]. Deciphering these mechanisms is essential for developing novel therapeutic strategies.

Multi-omics integration (genomics, transcriptomics, proteomics, metabolomics) provides unprecedented insights into CKM syndrome pathogenesis [48]. Systematic profiling of adipokine secretion patterns and their interactions with distant organs will:

Identify stage-specific metabolic signatures,Discover early biomarkers for timely intervention [49].

Adipose tissue heterogeneity complicates mechanistic studies. White, brown, and beige adipocytes exhibit distinct metabolic roles, influenced by genetic, environmental, and lifestyle factors. These variables collectively shape adipose function across CKM stages. Unraveling tissue-specific signaling networks will enable precision interventions.

2.5.2. Clinical Trial Imperatives

Robust clinical evidence is paramount for advancing CKM staging therapies. Large-scale, multicenter RCTs must:Validate novel therapies’ safety/efficacy,Establish foundations for personalized approaches.The EDOSURE trial exemplifies this, demonstrating differential responses to direct oral anticoagulants across patient subgroups and underscoring individualized treatment necessity.

Precision intervention development requires:Integrating psychosocial determinants with biomarker profiling.Systematically analyzing population-specific treatment responses.Future studies should optimize multidisciplinary strategies combining nutrition, exercise, and psychological support in clinical practice [50].

2.5.3. Technological and Policy Enablers

Digital health technologies(e.g.,remote monitoring platforms) enhance CKM management by:Improving patient engagement and adherence.Enabling real-time data-driven interventions.Evidence confirms their efficacy in risk factor control, hospitalization reduction, and cost savings.

Policy frameworks must prioritize:Funding for healthcare technology infrastructure.Regulatory standards for data security (e.g., HIPAA/GDPR compliance).

Clinician training in digital tool utilization.Concurrently, socioeconomic interventions—improving healthcare access, nutrition education, and food security in vulnerable communities—are essential for equitable CKM management. Synergizing technology and policy creates multidisciplinary solutions to reduce disease burden and improve quality of life.

3. Conclusion

The bidirectional cardiorenal interplay in chronic kidney disease (CKD) is increasingly recognized within the context of obesity-related metabolic disorders. The cardio-kidney-metabolic (CKM) syndrome staging system provides a scientific framework for organ-protective stratification and therapeutic guidance, offering novel perspectives for clinical practice.

Adipose tissue dysfunction constitutes a central pathophysiological node linking obesity-associated metabolic derangements to cardiorenal injury. Through mechanisms including chronic inflammation, endotoxin release, and metabolic dysregulation, it drives progressive cardiac and renal functional decline.Consequently, positioning it as a prime therapeutic target in CKM management.

Weight management strategiesexhibit dual efficacy:Pharmacotherapy: Novel anti-obesity agents (e.g.,GLP-1 receptor agonists) demonstrate significant cardiorenal protection in clinical trials.Lifestyle interventions: Remain foundational for cardiorenal health preservation.The DATA(Data-driven, Adaptive, Team-based, Algorithm-guided) multidisciplinary model emphasizes collaborative care among clinicians, dietitians, and psychologists. This framework leverages precision analytics for individualized treatment, optimizing CKM clinical outcomes.

Future research should prioritize: Elucidating molecular mechanisms underlying CKM progression.Validating therapeutic efficacy in diverse populations.Securing policy support for scalable implementation.Advancing adipose biology research, refining weight management protocols, and perfecting personalized frameworks hold promise for enhanced cardiorenal protection, reduced CKD/CVD incidence, and improved patient prognosis.